Mesoblast Pens Strategic Partnership for MPC-06-ID

Mesoblast Limited (ASX: MSB) has entered into strategic partnership with Grünenthal. This partnership would see both companies developing & commercialising MPC-06-ID – a phase III candidate for the treatment of chronic low back pain.

Both companies would collaborate on the study design for confirmatory Phase III trial in Europe, and the results would underpin the development for regulatory requirements in the US and Europe. Mesoblast would receive up to US$150 million prior to product launch, and additional commercialisation milestone payments.

By 12:21 PM, MSB was trading at A$1.74, up by 19.59% from the previous close.

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK